Bone Neoplasms

The supplied grounding supports secondary bone neoplasms arising from metastasis, but does not provide specific etiologic causes for primary bone neoplasms. It also notes genetic and secondary aspects in the literature, but no specific causal mutations or exposures are given.

The literature describes a distinctive bone tumor microenvironment made up of bone cells, immune cells, stromal cells, and vascular structures within a mineralized extracellular matrix. In osteosarcoma and bone metastatic cancer, this microenvironment can promote proliferation, migration, apoptosis resistance, drug resistance, immune escape, and metastatic progression, with roles for tumor-associated macrophages, other infiltrating immune cells, complement, exosomes, osteoclasts, and osteoblasts.

The supplied grounding does not identify specific risk factors for bone neoplasms. It does indicate that osteosarcoma is most commonly found in pediatric and adolescent patients, but this is a demographic association rather than a causal risk factor.

The grounding supports surgery, radiotherapy, and drug therapy as treatment modalities for bone neoplasms. It also indicates use or study of bone-targeted agents such as radium, radium-223, and zoledronic acid, and immunotherapy approaches including immune checkpoint inhibitors, CAR T cells, bispecific antibodies, modified NK cells/macrophages, dendritic cell vaccines, and cytokines in osteosarcoma.